MDM2 inhibitor Nutlin-3a suppresses proliferation and promotes apoptosis in osteosarcoma cells
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Restoring p53 activity by inhibiting the interaction between p53 and the mouse double minutes clone 2 (MDM2) offers an attractive approach to cancer therapy. Nutlin-3a is a small-molecule inhibitor that inhibits MDM2 binding to p53 and subsequent p53-dependent DNA damage signaling. In this study, we determined the efficacy of Nutlin-3a in inducing p53-mediated cell death in osteosarcoma (OS) cell lines both in vivo and in vitro. Targeted disruption of the p53-MDM2 interaction by Nutlin-3a stabilizes p53 and selectively activates the p53 pathway only in OS cells with wild-type p53, resulting in a pronounced anti-proliferative and cytotoxic effect due to G1 cell cycle arrest and apoptosis both in vitro and in vivo. p53 dependence of these alternative outcomes of Nutlin-3a treatment was shown by the abrogation of these effects when p53 was knocked-down by small interfering RNA. These data suggest that the disruption of p53-MDM2 interaction by Nutlin-3a might be beneficial for OS patients with MDM2 amplification and wt p53 status.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The IC50s reported in this study are consistent with previous reports showing that MDM2 amplified cancer cell lines (e.g. liposarcoma and osteosarcoma lines) are more sensitive to RG7112 or Nutlin-3 [25–28].”
From Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2 -Amplified and TP53 Wild-type Glioblastomas (2016) · cites this paper as [27]
Citations
Cites
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
mdm2 expression is induced by wild type p53 activity.
Barak, Y., Juven, T., Haffner, R., & Oren, M. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05678.x · Cited by 1,290
Principles of Tumor Suppression
Sherr, C. J. (2004) · Cell · doi:10.1016/s0092-8674(03)01075-4 · Cited by 1,034
p53 isoforms can regulate p53 transcriptional activity
Bourdon, J.-C., Fernandes, K., Murray-Zmijewski, F., Liu, G., Diot, A., Xirodimas, D. P., Saville, M. K., & Lane, D. P. (2005) · Genes & Development · doi:10.1101/gad.1339905 · Cited by 810
Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy
Tovar, C., Rosinski, J., Filipovic, Z., Higgins, B., Kolinsky, K., Hilton, H., Zhao, X., Vu, B. T., Qing, W., Packman, K., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507493103 · Cited by 708
MDM2 — master regulator of the p53 tumor suppressor protein
Momand, J., Wu, H.-H., & Dasgupta, G. (2000) · Gene · doi:10.1016/s0378-1119(99)00487-4 · Cited by 641
Principles and Practice of Pediatric Oncology
Labotka, R. J. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03540480082049 · Cited by 630
Research works printed but not linked: 1
- Rosen GF, Forscher CA, Mankin HJ, Selch MT, Bast RC, Kufe DW, Pollock RE, Weichselbaum RR, Holland JF, Frei E. Neoplasm of bone and soft tissue. Cancer Medicine, 2000, 1870-1902.
Cited by
The role of p53 in cancer drug resistance and targeted chemotherapy
Hientz, K., Mohr, A., Bhakta-Guha, D., & Efferth, T. (2017) · Oncotarget · doi:10.18632/oncotarget.13475 · Cited by 587
The MDM2-p53 pathway revisited
Subhasree, N., Jiangjiang, Q., Kalkunte, S., Minghai, W., & Ruiwen, Z. (2013) · The Journal of Biomedical Research · doi:10.7555/jbr.27.20130030 · Cited by 414
New targets and approaches in osteosarcoma
Gill, J., Ahluwalia, M. K., Geller, D., & Gorlick, R. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.09.003 · Cited by 273
Therapeutics targeting p53-MDM2 interaction to induce cancer cell death
Koo, N., Sharma, A. K., & Narayan, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23095005 · Cited by 153
TP53 in bone and soft tissue sarcomas
Thoenen, E. A., Curl, A., & Iwakuma, T. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.06.010 · Cited by 150
Targeting Intrinsically Disordered Transcription Factors: Changing the Paradigm
Tsafou, K., Tiwari, P. B., Forman-Kay, J. D., Metallo, S. J., & Toretsky, J. A. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.04.008 · Cited by 112
Verreault, M., Schmitt, C., Goldwirt, L., Pelton, K., Haidar, S., Levasseur, C., Guehennec, J., Knoff, D., Labussière, M., Marie, Y., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1015 · Cited by 114
Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas
Laroche-Clary, A., Chaire, V., Algeo, M.-P., Derieppe, M.-A., Loarer, F. L., & Italiano, A. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0482-3 · Cited by 111
“Limited preclinical data are available regarding the antitumour activity of nutlins in sarcomas [18, 21, 29].”
BackgroundMicroarray expression profile of long noncoding RNAs in human osteosarcoma
Li, J., Liu, L., Li, J., Chen, Y., Jiang, X.-W., Ouyang, Y., Liu, Y.-Q., Zhong, H., Li, H., & Xiao, T. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.02.083 · Cited by 95
Volsi, A. L., Scialabba, C., Vetri, V., Cavallaro, G., Licciardi, M., & Giammona, G. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b03711 · Cited by 92
Advances in targeted therapy for osteosarcoma based on molecular classification
Chen, Y., Liu, R., Wang, W., Wang, C., Zhang, N., Shao, X., He, Q., & Ying, M. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105684 · Cited by 91
Nutlin-Loaded Magnetic Solid Lipid Nanoparticles for Targeted Glioblastoma Treatment
Grillone, A. F., Battaglini, M., Moscato, S., Mattii, L., Fernández, C. D. J., Scarpellini, A., Gıorgı, M., Sinibaldi, E., & Ciofani, G. (2018) · Nanomedicine · doi:10.2217/nnm-2018-0436 · Cited by 82
Human glioblastoma multiforme: p53 reactivation by a novel MDM2 inhibitor
Costa, B., Bendinelli, S., Gabelloni, P., Da Pozzo, E., Daniele, S., Scatena, F., Vanacore, R., Campiglia, P., Bertamino, A., Gomez-Monterrey, I., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072281 · Cited by 79
“Indeed, it has been demonstrated that a number of small-molecule MDM2 inhibitors can disrupt the MDM2-p53 interaction, release p53 from negative control and activate the p53 pathway, leading to cell cycle arrest and apoptosis in a number of solid cancers and haematological malignancies [14–17].”
BackgroundMDM2: current research status and prospects of tumor treatment
Yao, Y., Zhang, Q., Li, Z., & Zhang, H. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03356-8 · Cited by 82
TP53 in Biology and Treatment of Osteosarcoma
Synoradzki, K. J., Bartnik, E., Czarnecka, A. M., Fiedorowicz, M., Firlej, W., Brodziak, A., Stasinska, A., Rutkowski, P. L., & Grieb, P. (2021) · Cancers · doi:10.3390/cancers13174284 · Cited by 70
Pharmacological Modulation of Ubiquitin-Proteasome Pathways in Oncogenic Signaling
Sharma, A., Khan, H., Singh, T. G., Grewal, A. K., Najda, A., Kawecka-Radomska, M., Kamel, M. S., Altyar, A. E., & Abdel‐Daim, M. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111971 · Cited by 67
Sampson, V. B., Gorlick, R. G., Kamara, D., & Kolb, E. A. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00132 · Cited by 57
Pharmacologic activation of wild-type p53 by nutlin therapy in childhood cancer
Maerken, T. V., Rihani, A., Goethem, A. V., Paepe, A. D., Speleman, F., & Vandesompele, J. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.11.002 · Cited by 51
He, X., Pang, Z., Zhang, X., Lan, T., Chen, H., Chen, M., Yang, H., Huang, J., Chen, Y., Zhang, Z., et al. (2018) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001125 · Cited by 51
Mutant p53 upregulates alpha-1 antitrypsin expression and promotes invasion in lung cancer
Shakya, R., Tarulli, G. A., Sheng, L., Lokman, N. A., Ricciardelli, C., Pishas, K. I., Selinger, C. I., Kohonen‐Corish, M. R. J., Cooper, W. A., Turner, A. G., et al. (2017) · Oncogene · doi:10.1038/onc.2017.66 · Cited by 43
Rivera-Valentin, R. K., Zhu, L., & Hughes, D. P. M. (2015) · Pediatric Drugs · doi:10.1007/s40272-015-0134-4 · Cited by 41
Precision Oncology in Sarcomas: Divide and Conquer
Pestana, R. C., Groisberg, R., Roszik, J., & Subbiah, V. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00247 · Cited by 40
Laroche, A., Chaire, V., Algeo, M.-P., Karanian, M., Fourneaux, B., & Italiano, A. (2017) · Oncotarget · doi:10.18632/oncotarget.16345 · Cited by 38
“There are only limited pre-clinical data regarding the anti-tumor activity of nutlins in sarcomas [20-22].”
BackgroundThe Targeted Therapies for Osteosarcoma via Six Major Pathways
Wang, S., Ren, Q., Li, G., Zhao, X., Zhao, X., & Zhang, Z. (2023) · Current Molecular Pharmacology · doi:10.2174/1874467217666230821142839 · Cited by 34
Lei, C., Tang, H. R., Ye, C., You, C., Zhang, J., Zhang, C.-Y., Xiong, W., Su, H., & Zhang, C. (2017) · Scientific Reports · doi:10.1038/s41598-017-10927-5 · Cited by 30
Long non‑coding RNA PCAT6 promotes the development of osteosarcoma by increasing MDM2 expression
Guan, X., Xu, Y., & Zheng, J.-F. (2020) · Oncology Reports · doi:10.3892/or.2020.7813 · Cited by 27
p53 inhibition by MDM2 in human pterygium
Cao, D., Ng, T. K., Yip, Y. W. Y., Young, A. L., Pang, C. P., Chu, W. K., & Jhanji, V. (2018) · Experimental Eye Research · doi:10.1016/j.exer.2018.06.021 · Cited by 27
Naghib, S. M., Ahmadi, B., & Mozafari, M. R. (2024) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266293173240506054439 · Cited by 25
Karimi, K., Mojtabavi, S., Tehrany, P. M., Nejad, M. M., Rezaee, A., Mohtashamian, S., Hamedi, E., Yousefi, F., Salmani, F., Zandieh, M. A., et al. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.124935 · Cited by 21
Sunil, V., Mozhi, A., Zhan, W., Teoh, J. H., & Wang, C. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120974 · Cited by 21
Impacts of Nutlin-3a and exercise on murine double minute 2–enriched glioma treatment
Chen, Y., Fan, Z., Luo, Z., Kang, X., Wan, R., Li, F., Lin, W., Han, Z., Qi, B., Lin, J., et al. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-23-00875 · Cited by 20
Roy, P., Biswas, A., Deepak, K., & Mandal, M. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188734 · Cited by 20
Kanagasabai, T., Venkatesan, T., Natarajan, U., Alobid, S. E., Alhazzani, K., Algahtani, M., & Rathinavelu, A. (2019) · Cellular Signalling · doi:10.1016/j.cellsig.2019.109435 · Cited by 19
Putri, H. E., Nutho, B., Rungrotmongkol, T., Sritularak, B., Vinayanuwattikun, C., & Chanvorachote, P. (2021) · Phytomedicine · doi:10.1016/j.phymed.2021.153534 · Cited by 17
Kiptiyah, K., Widodo, W., Ciptadi, G., Aulanni’am, A., Widodo, M. A., & Sumitro, S. B. (2017) · Journal of Taibah University Medical Sciences · doi:10.1016/j.jtumed.2017.05.012 · Cited by 16
Sharma, S., & Kumar, P. (2023) · ACS Omega · doi:10.1021/acsomega.2c07904 · Cited by 15
Han, N., Park, H., Ko, S., & Moon, P. (2024) · Antioxidants · doi:10.3390/antiox13030380 · Cited by 15
SATB2 and MDM2 Immunoexpression and Diagnostic Role in Primary Osteosarcomas of the Jaw
Owosho, A. A., Ladeji, A. M., Adesina, O. M., Adebiyi, K. E., Olajide, M. A., Okunade, T., Palmer, J., Kehinde, T., Vos, J. A., Cole, G., et al. (2021) · Dentistry Journal · doi:10.3390/dj10010004 · Cited by 14
Chen, W., Liu, Q., Fu, B., Liu, K., & Jiang, W. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.07.015 · Cited by 13
RetractedHonoki, K., & Tsujiuchi, T. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2013.820010 · Cited by 13
Islamian, J. P., Mohammadi, M., & Baradaran, B. (2014) · PubMed Central · doi:10.7497/j.issn.2095-3941.2014.02.002 · Cited by 12
Schubert, N. A., Lowery, C. D., Bergthold, G., Köster, J., Eleveld, T. F., Rodríguez, A. I. E., Jones, D., Vassal, G., Stancato, L. F., Pfister, S. M., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.01.027 · Cited by 12
Laroche, A., Tran-Cong, K., Chaire, V., Lagarde, P., Hostein, I., Coindre, J., Chibon, F., Neuville, A., Lesluyes, T., Lucchesi, C., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0137794 · Cited by 11
The Role of p53‐Mediated Cellular Senescence in Idiopathic Pulmonary Fibrosis
Jin, Y., Jiang, M., Bu, W., Zhou, Y., Tang, J., Bao, S., Zhao, R., Zhao, X., & Cheng, D. (2025) · Comprehensive physiology · doi:10.1002/cph4.70041 · Cited by 9
Transcription-associated DNA DSBs activate p53 during hiPSC-based neurogenesis
Michel, N., Raimer, H. M., Atkin, N. D., Arshad, U., Al-Humadi, R. N., Singh, S., Manukyan, A., Gore, L. N., Burbulis, I. E., Wang, Y., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-16516-5 · Cited by 8
Pharmacological Inhibition of MDM2 Induces Apoptosis in p53-Mutated Triple-Negative Breast Cancer
On, J. L., Ghaderi, S., Rittmann, C., Hoffmann, G., Gier, F., Woloschin, V., Tu, J., Bhatia, S., Kulik, A., Niederacher, D., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031078 · Cited by 7
Cucurbitacin B in cancer: A comprehensive review of its targets and molecular mechanisms
Mi, L., He, T., Lei, D., Lei, D., Su, A., Wei, T., Li, Z., & Wu, W. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117240 · Cited by 6
Iron-Related Metabolic Targets in the Treatment of Osteosarcoma: Research Progress and Prospects
Buglione, A., Gioia, M., Sinibaldi, F., Marini, S., & Ciaccio, C. (2025) · Biomedicines · doi:10.3390/biomedicines13112756 · Cited by 6
Shanel, G., Hsieh, T.-H. S., Cattoglio, C., Haham, H. A., Chou, H.-J., Li, J. Z., Shamir, R., Darzacq, X., & Elkon, R. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf607 · Cited by 5
Fibronectin Modulates the Expression of miRNAs in Prostate Cancer Cell Lines
Martinucci, B., Cucielo, M. S., Minatel, B. C., Cury, S. S., Caxali, G. H., Aal, M. C. E., Felisbino, S. L., Pinhal, D., Carvalho, R. F., & Delella, F. K. (2022) · Frontiers in Veterinary Science · doi:10.3389/fvets.2022.879997 · Cited by 5
The Role of an Oncoprotein CIP2A in Breast Cancer
Laine, A. (2013) · UTUPub (University of Turku) · Cited by 5
The evolution of Nutlins as p53-MDM2 inhibitors
Bazanov, D. R., & Lozinskaya, N. A. (2025) · Medicinal Chemistry Research · doi:10.1007/s00044-025-03492-4 · Cited by 4
Drug-Induced p53 Activation Limits Pancreatic Cancer InitiationPreprint
Twardowski, J. J., Heist, T. I., Soares, Z. G., Berry, E. S., Ruffolo, L. I., Pröschel, C., & Mello, S. S. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.29.595146 · Cited by 4
Verma, S., & Pandey, A. K. (2021) · Network Modeling Analysis in Health Informatics and Bioinformatics · doi:10.1007/s13721-021-00286-7 · Cited by 3
Yang, C., Yu, Y., Wang, Y., Cai, Z., Zhao, Y., Ma, H., Xu, J., Zhu, H., Ren, T., Tang, X., et al. (2026) · Bone Reports · doi:10.1016/j.bonr.2026.101930 · Cited by 1
Deng, W., Gao, S., Yan, L., Su, Q., & Chen, S. (2026) · Pharmaceuticals · doi:10.3390/ph19030476 · Cited by 1
Ricciardi, G., Fiorentino, V., Tralongo, P., Lentini, M., Pepe, L. R., Zuccalà, V., Ballato, M., Giuffrè, G., Ieni, A., Zampogna, B., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1823738 · Cited by 1
Ulrich, M. P. (2016) · doi:10.5282/edoc.19822 · Cited by 1
Analysis of Immune Infiltration Pattern in Osteosarcoma and Its Clinical SignificancePreprint
Yuan, W., Deng, Y., Ren, E., Zhang, G., Wu, Z., & Xie, Q. (2020) · doi:10.21203/rs.3.rs-91597/v1 · Cited by 1
Lavoll, C. (2013) · NORA - Norwegian Open Research Archives
Ciblage de la voie PI3K/mTOR dans les léiomyosarcomes : sensibilité et mécanismes de résistance
Fourneaux, B. (2017) · theses.fr (ABES) · doi:10.70675/3f0ab847z27b0z4e03zad9ez3cb6ed282770
Regulation of Gene Expression by the Mediator Kinase Cdk19
Audetat, K. A. (2016) · CU Scholar (University of Colorado Boulder)
Investigating mechanisms of Epstein-Barr virus reactivation in epithelial cells
Žentelis, S. (2018) · Oxford University Research Archive (ORA) (University of Oxford) · doi:10.5287/ora-z6o8gqv0w
Putri, H. E., & Chanvorachote, P. (2021) · Chula Digiverse · doi:10.58837/chula.the.2021.314
Osteosarcoma: concepts and prospects through the lens of translational science
Shukla, S. G., Masroor, H., Pandey, S., Chaurasiya, R., Gupta, R., Arshad, M., Misra, A., & Gupta, M. (2024) · Current Science · doi:10.18520/cs/v127/i11/1287-1300
Mariana Flávia da, M. O. T. A. (2013) · Americanae (AECID Library)
Ubiquitination in cardiovascular diseases: From molecular mechanisms to therapeutic targeting
Wang, J.-Y., Zhang, T., Yang, N., Hao, P.-H., Zheng, Y., & Wen, R. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103218
Martinucci, B., Cucielo, M. S., Minatel, B. C., Cury, S. S., Caxali, G. H., Aal, M. C. E., Felisbino, S. L., Pinhal, D., Carvalho, R. F., & Delella, F. K. (2022) · doi:10.3389/fvets.2022.879997.s002
Metadata
- Authors
- Wang, B., Fang, L., Zhao, H., Xiang, T., & Wang, D.
- Affiliations
- Chinese People's Armed Police Force (CN)
- Chinese People's Armed Police General Hospital (CN)
- Qingdao University (CN)
- Venue
- Acta Biochimica et Biophysica Sinica
- Published
- 2012-08-01
- Volume
- 44
- Issue
- 8
- Pages
- 685-691
- ISSN
- 1672-9145 (ISSN-L)
- OpenAlex
- W2140723802
- Cited by
- 58
- References
- 33
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 5 · 2023: 3 · 2022: 4 · 2021: 8 · 2020: 3 · 2019: 3 · 2018: 5 · 2017: 7 · 2016: 1 · 2015: 3 · 2014: 1 · 2013: 7 · 2012: 1
- FWCI
- 1.90
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Acta Biochimica et Biophysica Sinica (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Keywords
- Nutlin-3a, MDM2 inhibitors, osteosarcoma, p53, p53-MDM2 interaction, apoptosis, cell proliferation, G1 cell cycle arrest, MDM2 amplification, small molecule inhibitors
- MeSH terms
- Animals, Cell Cycle, DNA Damage, Humans, Imidazoles, Neoplasm Transplantation, Piperazines, Osteosarcoma, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53, Mice, SCID, Apoptosis, RNA, Small Interfering, Cell Line, Tumor, Cell Proliferation, Mice, Proto-Oncogene Proteins c-mdm2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.